Compound Efficacy studies

Using an in vivo model and cutting-edge technology, Nagi Bioscience delivers precise, actionable results to help researchers uncover strategies to measure the efficacy of their compounds. 

Our solution enables ethical, efficient testing, providing valuable insights into the treatment efficacy. With a streamlined workflow, Nagi Bioscience accelerates the discovery and development of candidate therapeutics addressing patient diseases and ultimately improving the quality of life.

C. elegans: A gateway to drug discovery

Caenorhabditis elegans is a powerful and validated model for testing therapeutics efficacy in vivo. With a wide array of precisely quantifiable phenotypes and conserved human genetic pathways, it enables precise measurement of drug efficacy. Its short lifespan and genetic tractability support high-throughput screening and precise modeling of disease-associated proteins.

Research using C. elegans has uncovered key insights into several human diseases, advancing therapeutic discovery. In conclusion, C. elegans offers an efficient, translationally relevant platform to accelerate compound development and ultimately decreasing the time to market of therapeutics.

ALS model C elegans on SydLab One
YFP-tagged SOD1 in the ALS C. elegans model (day 6 on SydLab™ One).

In vivo efficacy studies, at in vitro scale.

Our standardized protocols and automated workflow ensure consistent, actionable results.

To support your publications.

The much-vaunted C. elegans model delivers high translational value.

Fluorescence markers can be easily monitored and quantified for functional studies and identification of mechanism of action. Disease models can also be used (rare diseases, infectious diseases, metabolic diseases).

The advanced high-content imaging of our SydLab™ One platform enables the visualization and analysis of diverse phenotypes, supporting wider range of applications.


From research to results: Our approach

  1. Synchronized populations of a specific disease model C. elegans are injected into the SydLab™ One platform (day 0).
  2. The SydLab™ One platform tightly controls the liquid environment to which each worm is exposed, including the treatments to be tested.
  3. Images or videos are acquired via time-lapse microscopy at the desired frequency.
  4. Our AI-based algorithm detects growth, reproductive and death parameters of individual C. elegans, and provide a detailed analysis for the nematode population.
  5. The experiment ends at the desired time.

Readouts

  • Growth dynamics and parameters
  • Sexual maturity
  • Egg accumulation and embryo survival
  • Larvae emergence and accumulation
  • Progeny size and growth
  • Healthspan: Reproductive, Motility, Intestinal Atrophy.
  • Lifespan: Survival.
  • Fluorescence: Functional, Mechanism of Action.

Case Study: Efficacy assessment

Using Nagi Bioscience’s fully automated solution, we assessed the dose-response for the “mitochondrial unfolded protein response” activation (HSP6-GFP reporter C. elegans strain) upon exposure to different concentrations of doxycycline (Dox), 9-tert-butyl doxycycline (9-TB), or anhydrotetracycline 2 (ATc).

The SydLab™ One platform quantified the dose-dependent effects of Dox, 9-TB and ATc to the the “mitochondrial unfolded protein response”, monitored using the fluorescent bio-marker HSP6-GFP. In summary, 9-TB and ATc were more efficacious at lower doses to induce the “mitochondrial unfolded protein response” relative to Dox.

Karl Alex Hedin, PhD

“Their services revealed new insights and opened up exciting possibilities for exploring the potential of our strains in health applications related to healthy aging, helping us advance our research further.”

Karl Alex Hedin, PhD

Post-Doctoral Researcher, DTU Biosustain, The Novo Nordisk Foundation Centre for Biosustainability

Erez Aminov

We are very pleased with Nagi Bioscience. Their innovative technology has been instrumental in allowing us to gather critical scientific data quickly, providing invaluable insights that significantly advance our research in longevity.

Erez Aminov

CEO, Telomir Pharmaceuticals, Inc.

Irina Fingerhut

Their high-throughput approach provided clear, quantifiable insights into the lifespan and functional effects of our lead combinations— critical data that helped de-risk and prioritize our therapeutic strategy.

Irina Fingerhut

Co-Founder/Sole Director, ElixIRA Pharma AG

Our commitment to you and your team

At Nagi Bioscience, we are more than just a service laboratory. We are a strategic partner dedicated to your success. Our team of experts brings 50+ years of experience, a passion for innovation, and a commitment to delivering actionable insights.

Initial Discussions:
Understanding your requirements

Send us your compounds of interest

Project kick-off:
Execute with Expertise

Report delivery:
High quality reports with actionable insights